REFLUDAN Side Effects

6880744-2 | Heparin-induced Thrombocytopenia, Subdural Haemorrhage
on Jun 01, 2010 Male patient from IRELAND , 70 years of age, was diagnosed with pulmonary embolism (What is pulmonary embolism?) and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: heparin-induced thrombocytopenia, subdural haemorrhage. Refludan dosage: . During the same period patient was treated with INNOHEP (View Innohep Review and Innohep Label ), PARACETAMOL (1gm As Needed) (View Paracetamol Review and Paracetamol Label ), CYCLIMORPH (5 - 10 Mg (as Needed)) (View Cyclimorph Review and Cyclimorph Label ), PROCHLORPERAZINE (Total Daily Dose: 37.5 Mg) (View Prochlorperazine Review and Prochlorperazine Label ), TRAMADOL HYDROCHLORIDE (Total Daily Dose: 200 Mg) (View Tramadol Hydrochloride Review and Tramadol Hydrochloride Label ), CYCLIZINE (Total Daily Dose: 150 Mg) (View Cyclizine Review and Cyclizine Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), CITALOPRAM HYDROBROMIDE (Total Daily Dose: 20 Mg) (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ).

6767083-5 | Heparin-induced Thrombocytopenia, Subdural Haemorrhage
Patient was taking Refludan (View Usage). Patient had the following side effects: heparin-induced thrombocytopenia, subdural haemorrhage on Jun 01, 2010 from IRELAND Additional patient health information: Male patient , 70 years of age, was diagnosed with pulmonary embolism (What is pulmonary embolism?) and. Refludan dosage: . During the same period patient was treated with INNOHEP (View Innohep Review and Innohep Label ), PARACETAMOL (1gm As Needed) (View Paracetamol Review and Paracetamol Label ), CYCLIMORPH (5 - 10 Mg (as Needed)) (View Cyclimorph Review and Cyclimorph Label ), PROCHLORPERAZINE (Total Daily Dose: 37.5 Mg) (View Prochlorperazine Review and Prochlorperazine Label ), TRAMADOL (Total Daily Dose: 200 Mg) (View Tramadol Review and Tramadol Label ), CYCLIZINE (Total Daily Dose: 150 Mg) (View Cyclizine Review and Cyclizine Label ), ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), CITALOPRAM (Total Daily Dose: 20 Mg) (View Citalopram Review and Citalopram Label ).

6737919-2 | Heparin-induced Thrombocytopenia, Subdural Haemorrhage
Adverse event was reported on May 13, 2010 by a Male patient taking Refludan (View Usage) (Dosage: ) . Location: IRELAND , 70 years of age, After Refludan was administered, patient had the following side effects: heparin-induced thrombocytopenia, subdural haemorrhage. During the same period patient was treated with INNOHEP (View Innohep Review and Innohep Label ), SODIUM HEPARIN (View Sodium Heparin Review and Sodium Heparin Label ).

6715022-5 | Peripheral Ischaemia
on Apr 08, 2010 Male patient from UNITED STATES , 62 years of age, was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: peripheral ischaemia. Refludan dosage: . Patient was hospitalized.


6715021-3 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
on Apr 21, 2010 Male patient from GERMANY , 25 years of age, weighting 264.6 lb, was diagnosed with platelet aggregation inhibition and was treated with Refludan (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock. Refludan dosage: As Used: 0.6 To 1 Mg/h. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6715020-1 | Heparin-induced Thrombocytopenia, Subdural Haemorrhage
Patient was taking Refludan (View Usage). After Refludan was administered, patient had the following side effects: heparin-induced thrombocytopenia, subdural haemorrhage on Apr 27, 2010 from IRELAND Additional patient health information: Male patient , 70 years of age, . Refludan dosage: . During the same period patient was treated with INNOHEP (View Innohep Review and Innohep Label ).

6706085-1 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
Adverse event was reported on Apr 21, 2010 by a Male patient taking Refludan (View Usage) (Dosage: As Used: 0.6 To 1 Mg/h) was diagnosed with platelet aggregation inhibition and. Location: GERMANY , 25 years of age, weighting 264.6 lb, Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6704587-5 | Primary Mediastinal Large B-cell Lymphoma, Thrombosis
on Apr 15, 2010 Female patient from UNITED STATES , 28 years of age, was treated with Refludan (View Usage). Patient had the following side effects: primary mediastinal large b-cell lymphoma, thrombosis. Refludan dosage: . During the same period patient was treated with CEPHALEXIN (View Cephalexin Review and Cephalexin Label ), PROTON PUMP INHIBITOR (View Proton-pump Inhibitor Review and Proton-pump Inhibitor Label ), NICARDIPINE HYDROCHLORIDE (View Nicardipine Hydrochloride Review and Nicardipine Hydrochloride Label ), OXYGEN (View Oxygen Review and Oxygen Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), DOBUTAMINE HCL (View Dobutamine Hcl Review and Dobutamine Hcl Label ). Patient was hospitalized.

6704586-3 | Angina Pectoris
on Jan 13, 2010 Male patient from GREECE , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: angina pectoris. Refludan dosage: . During the same period patient was treated with LEPUR (View Lepur Review and Lepur Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), FRUMIL (View Frumil Review and Frumil Label ), ZURCASOL (View Zurcasol Review and Zurcasol Label ), LACIPIL (View Lacipil Review and Lacipil Label ).

6704585-1 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
Patient was taking Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock on Apr 15, 2010 from GERMANY Additional patient health information: Male patient , 25 years of age, weighting 264.6 lb, was diagnosed with platelet aggregation inhibition and. Refludan dosage: As Used: 0.6 To 1 Mg/h. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6704584-X | Peripheral Ischaemia
Adverse event was reported on Apr 08, 2010 by a Male patient taking Refludan (View Usage) (Dosage: ) . Location: UNITED STATES , 62 years of age, Patient had the following side effects: peripheral ischaemia. Patient was hospitalized.

6698031-4 | Primary Mediastinal Large B-cell Lymphoma, Thrombosis
on Apr 15, 2010 Female patient from UNITED STATES , 28 years of age, was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: primary mediastinal large b-cell lymphoma, thrombosis. Refludan dosage: . During the same period patient was treated with CEPHALEXIN (View Cephalexin Review and Cephalexin Label ), PROTON PUMP INHIBITOR (View Proton-pump Inhibitor Review and Proton-pump Inhibitor Label ), NICARDIPINE HYDROCHLORIDE (View Nicardipine Hydrochloride Review and Nicardipine Hydrochloride Label ), OXYGEN (View Oxygen Review and Oxygen Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), DOBUTAMINE (View Dobutamine Review and Dobutamine Label ). Patient was hospitalized.

6698029-6 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
on Apr 15, 2010 Male patient from GERMANY , 25 years of age, weighting 264.6 lb, was diagnosed with platelet aggregation inhibition and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock. Refludan dosage: As Used: 0.6 To 1 Mg/h. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6688023-3 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
Patient was taking Refludan (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock on Mar 30, 2010 from GERMANY Additional patient health information: Male patient , 25 years of age, weighting 264.6 lb, was diagnosed with platelet aggregation inhibition and. Refludan dosage: As Used: 0.6 To 1 Mg/h. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6688022-1 | Multi-organ Failure, Pulmonary Embolism
Adverse event was reported on Apr 09, 2010 by a Male patient taking Refludan (View Usage) (Dosage: ) was diagnosed with heparin-induced thrombocytopenia, postoperative care and. Location: GERMANY , 61 years of age, After Refludan was administered, patient had the following side effects: multi-organ failure, pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ).

6688016-6 | Primary Mediastinal Large B-cell Lymphoma, Thrombosis
on Feb 05, 2010 Female patient from UNITED STATES , 28 years of age, was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: primary mediastinal large b-cell lymphoma, thrombosis. Refludan dosage: . During the same period patient was treated with CEPHALEXIN (View Cephalexin Review and Cephalexin Label ), PROTON PUMP INHIBITOR (View Proton-pump Inhibitor Review and Proton-pump Inhibitor Label ), NICARDIPINE HYDROCHLORIDE (View Nicardipine Hydrochloride Review and Nicardipine Hydrochloride Label ), OXYGEN (View Oxygen Review and Oxygen Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), DOBUTAMINE (View Dobutamine Review and Dobutamine Label ). Patient was hospitalized.

6682401-4 | Primary Mediastinal Large B-cell Lymphoma, Thrombosis
on Feb 05, 2010 Female patient from UNITED STATES , 28 years of age, was treated with Refludan (View Usage). Patient had the following side effects: primary mediastinal large b-cell lymphoma, thrombosis. Refludan dosage: . During the same period patient was treated with CEPHALEXIN (View Cephalexin Review and Cephalexin Label ), PROTON PUMP INHIBITOR (View Proton-pump Inhibitor Review and Proton-pump Inhibitor Label ), NICARDIPINE HYDROCHLORIDE (View Nicardipine Hydrochloride Review and Nicardipine Hydrochloride Label ), OXYGEN (View Oxygen Review and Oxygen Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), DOBUTAMINE (View Dobutamine Review and Dobutamine Label ). Patient was hospitalized.

6682400-2 | Bronchopulmonary Aspergillosis, Disseminated Intravascular Coagulation, Septic Shock
Patient was taking Refludan (View Usage). After Refludan was administered, patient had the following side effects: bronchopulmonary aspergillosis, disseminated intravascular coagulation, septic shock on Mar 30, 2010 from GERMANY Additional patient health information: Male patient , 25 years of age, weighting 264.6 lb, was diagnosed with platelet aggregation inhibition and. Refludan dosage: As Used: 0.6 To 1 Mg/h. During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROTAMINE SULFATE (View Protamine Sulfate Review and Protamine Sulfate Label ), ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ).

6676079-3 | Angina Pectoris
Adverse event was reported on Jan 13, 2010 by a Male patient taking Refludan (View Usage) (Dosage: ) was diagnosed with heparin-induced thrombocytopenia and. Location: GREECE , 69 years of age, Patient experienced the following unwanted or unexpected effects: angina pectoris. During the same period patient was treated with LEPUR (View Lepur Review and Lepur Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), FRUMIL (View Frumil Review and Frumil Label ), ZURCASOL (View Zurcasol Review and Zurcasol Label ), LACIPIL (View Lacipil Review and Lacipil Label ).

6674411-8 | Angina Pectoris
on Jan 13, 2010 Male patient from GREECE , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and was treated with Refludan (View Usage). Patient had the following side effects: angina pectoris. Refludan dosage: . During the same period patient was treated with LEPUR (View Lepur Review and Lepur Label ), OLMESARTAN MEDOXOMIL (View Olmesartan Medoxomil Review and Olmesartan Medoxomil Label ), FRUMIL (View Frumil Review and Frumil Label ), ZURCASOL (View Zurcasol Review and Zurcasol Label ), LACIPIL (View Lacipil Review and Lacipil Label ).

6670857-2 | Vascular Insufficiency, Vena Cava Thrombosis
on Jan 05, 2010 Female patient from UNITED STATES , 51 years of age, was diagnosed with trousseau's syndrome and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: vascular insufficiency, vena cava thrombosis. Refludan dosage: . During the same period patient was treated with PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6670855-9 | Angina Pectoris
Patient was taking Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: angina pectoris on Dec 14, 2009 from GREECE Additional patient health information: Male patient , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and. Refludan dosage: .

6617346-9 | Haemorrhage
Adverse event was reported on Sep 16, 2009 by a Female patient taking Refludan (View Usage) (Dosage: ) . Location: UNITED STATES , 57 years of age, Patient had the following side effects: haemorrhage.

6520567-7 | Angina Pectoris
on Dec 14, 2009 Male patient from GREECE , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: angina pectoris. Refludan dosage: .

6516486-2 | Vascular Insufficiency, Vena Cava Thrombosis
on Dec 10, 2009 Female patient from UNITED STATES , 51 years of age, was diagnosed with trousseau's syndrome and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: vascular insufficiency, vena cava thrombosis. Refludan dosage: . During the same period patient was treated with PACLITAXEL (View Paclitaxel Review and Paclitaxel Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.

6515779-2 | Angina Pectoris
Patient was taking Refludan (View Usage). Patient had the following side effects: angina pectoris on Nov 27, 2009 from GREECE Additional patient health information: Male patient , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and. Refludan dosage: .

6515760-3 | Cardio-respiratory Arrest, Deep Vein Thrombosis, Pulmonary Infarction, Renal Infarct, Respiratory Failure, Splenic Infarction, Upper Gastrointestinal Haemorrhage
Adverse event was reported on Dec 01, 2009 by a Female patient taking Refludan (View Usage) (Dosage: ) was diagnosed with immunosuppression and. Location: UNITED STATES , 49 years of age, After Refludan was administered, patient had the following side effects: cardio-respiratory arrest, deep vein thrombosis (What is deep vein thrombosis?), pulmonary infarction, renal infarct, respiratory failure, splenic infarction, upper gastrointestinal haemorrhage. During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), PLASMA EXCHANGES (View Plasma Exchanges Review and Plasma Exchanges Label ).

6515745-7 | Gangrene, Gas Gangrene, Graft Thrombosis, Heparin-induced Thrombocytopenia, Leg Amputation
on Nov 09, 2009 Male patient from ITALY , 55 years of age, was diagnosed with peripheral ischaemia and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: gangrene, gas gangrene, graft thrombosis, heparin-induced thrombocytopenia, leg amputation. Refludan dosage: . During the same period patient was treated with HEPARIN (/24 H) (View Heparin Review and Heparin Label ).

6500018-9 | Cardio-respiratory Arrest, Deep Vein Thrombosis, Pulmonary Infarction, Renal Infarct, Respiratory Failure, Splenic Infarction, Upper Gastrointestinal Haemorrhage
on Dec 01, 2009 Female patient from UNITED STATES , 49 years of age, was diagnosed with immunosuppression and was treated with Refludan (View Usage). Patient had the following side effects: cardio-respiratory arrest, deep vein thrombosis (What is deep vein thrombosis?), pulmonary infarction, renal infarct, respiratory failure, splenic infarction, upper gastrointestinal haemorrhage. Refludan dosage: . During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), PLASMA EXCHANGES (View Plasma Exchanges Review and Plasma Exchanges Label ).

6492317-4 | Angina Pectoris
Patient was taking Refludan (View Usage). After Refludan was administered, patient had the following side effects: angina pectoris on Nov 27, 2009 from GREECE Additional patient health information: Male patient , 69 years of age, was diagnosed with heparin-induced thrombocytopenia and. Refludan dosage: .

6449987-6 | Gangrene, Graft Thrombosis
Adverse event was reported on Nov 09, 2009 by a Male patient taking Refludan (View Usage) (Dosage: ) was diagnosed with peripheral ischaemia and. Location: ITALY , 55 years of age, Patient experienced the following unwanted or unexpected effects: gangrene, graft thrombosis. During the same period patient was treated with HEPARIN (/24 H) (View Heparin Review and Heparin Label ).

6408105-0 | Abdominal Pain, Cholangitis Sclerosing, Hepatic Haematoma, Hepatic Haemorrhage, Perirenal Haematoma
on Oct 09, 2009 Female patient from UNITED STATES , 64 years of age, was diagnosed with heparin-induced thrombocytopenia, hepatic haemorrhage and was treated with Refludan (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), cholangitis sclerosing, hepatic haematoma, hepatic haemorrhage, perirenal haematoma. Refludan dosage: . During the same period patient was treated with PLATELETS (6 Units) (View Platelets Review and Platelets Label ). Patient was hospitalized.

6384965-7 | Abdominal Pain, Cholangitis Sclerosing, Hepatic Haematoma, Hepatic Haemorrhage, Perirenal Haematoma
on Sep 23, 2009 Female patient from UNITED STATES , 64 years of age, was diagnosed with heparin-induced thrombocytopenia, hepatic haemorrhage and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), cholangitis sclerosing, hepatic haematoma, hepatic haemorrhage, perirenal haematoma. Refludan dosage: . During the same period patient was treated with PLATELETS (6 Units) (View Platelets Review and Platelets Label ). Patient was hospitalized.

6384960-8 | Haemorrhage
Patient was taking Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: haemorrhage on Sep 16, 2009 from UNITED STATES Additional patient health information: Female patient , 57 years of age, . Refludan dosage: .

6378604-9 | Renal Failure
Adverse event was reported on Aug 20, 2009 by a Male patient taking Refludan (View Usage) (Dosage: 0.0125 Mg/kg/h) was diagnosed with deep vein thrombosis (What is deep vein thrombosis?) and. Location: FRANCE , 55 years of age, Patient had the following side effects: renal failure. During the same period patient was treated with ACENOCOUMAROL (View Acenocoumarol Review and Acenocoumarol Label ).

6373595-9 | Haemorrhage
on Sep 16, 2009 Female patient from UNITED STATES , 57 years of age, was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: haemorrhage. Refludan dosage: .

6343860-X | Haemorrhage
on Aug 26, 2009 Female patient from UNITED STATES , 57 years of age, was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: haemorrhage. Refludan dosage: Dose Was Canceled. Patient was hospitalized.

6340587-5 | Renal Failure
Patient was taking Refludan (View Usage). Patient had the following side effects: renal failure on Aug 20, 2009 from FRANCE Additional patient health information: Male patient , 55 years of age, was diagnosed with deep vein thrombosis (What is deep vein thrombosis?) and. Refludan dosage: 0.0125 Mg/kg/h. During the same period patient was treated with ACENOCOUMAROL (View Acenocoumarol Review and Acenocoumarol Label ).

6306446-9 | Depressed Level Of Consciousness, Haemorrhage Intracranial, Melaena, Muscle Contractions Involuntary, Respiratory Arrest, Thrombocytopenia
Adverse event was reported on Aug 02, 2009 by a Male patient taking Refludan (View Usage) (Dosage: 100 Mg, Continuous) was diagnosed with heparin-induced thrombocytopenia, hypertension, hypersensitivity, depression (What is depression?), pain (What is pain?) and. Location: UNITED STATES , 61 years of age, weighting 229.3 lb, After Refludan was administered, patient had the following side effects: depressed level of consciousness, haemorrhage intracranial, melaena, muscle contractions involuntary, respiratory arrest, thrombocytopenia. During the same period patient was treated with DOXAZOSIN (Unit Dose: 1 Mg) (View Doxazosin Review and Doxazosin Label ), NIFEDIPINE (Unit Dose: 30 Mg) (View Nifedipine Review and Nifedipine Label ), DIPHENHYDRAMINE HCL (Unit Dose: 25 Mg) (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), SERTRALINE (Unit Dose: 150 Mg) (View Sertraline Review and Sertraline Label ), ACETAMINOPHEN AND HYDROCODONE BITARTRATE (Unk, As Req'd) (View Acetaminophen And Hydrocodone Bitartrate Review and Acetaminophen And Hydrocodone Bitartrate Label ).

6294892-1 | Haemorrhage, Multi-organ Failure
on Jun 17, 2009 Male patient from SWITZERLAND , 72 years of age, weighting 198.4 lb, was diagnosed with heparin-induced thrombocytopenia, sedation, infection (What is infection?) and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: haemorrhage, multi-organ failure. Refludan dosage: 0.005 Mg/kg/hour ( Over 1 Month). During the same period patient was treated with DANAPAROID (View Danaparoid Review and Danaparoid Label ), PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), TIMENTIN (View Timentin Review and Timentin Label ).

6294568-0 | Depressed Level Of Consciousness, Haemorrhage Intracranial, Melaena, Muscle Contractions Involuntary, Respiratory Arrest, Thrombocytopenia
on May 11, 2009 Male patient from UNITED STATES , 61 years of age, weighting 229.3 lb, was diagnosed with heparin-induced thrombocytopenia, hypertension, hypersensitivity, depression (What is depression?), pain (What is pain?) and was treated with Refludan (View Usage). Patient had the following side effects: depressed level of consciousness, haemorrhage intracranial, melaena, muscle contractions involuntary, respiratory arrest, thrombocytopenia. Refludan dosage: 100 Mg, Continuous. During the same period patient was treated with DOXAZOSIN MESYLATE (Unit Dose: 1 Mg) (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), NIFEDIPINE (Unit Dose: 30 Mg) (View Nifedipine Review and Nifedipine Label ), DIPHENHYDRAMINE HCL (Unit Dose: 25 Mg) (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), SERTRALINE (Unit Dose: 150 Mg) (View Sertraline Review and Sertraline Label ), ACETAMINOPHEN AND HYDROCODONE BITARTRATE (Unk, As Req'd) (View Acetaminophen And Hydrocodone Bitartrate Review and Acetaminophen And Hydrocodone Bitartrate Label ).

6235863-0 | Chest Discomfort, Dyspnoea, Hypotension, Loss Of Consciousness
Patient was taking Refludan (View Usage). After Refludan was administered, patient had the following side effects: chest discomfort, dyspnoea, hypotension, loss of consciousness on May 21, 2009 from UNITED STATES Additional patient health information: Female patient , 88 years of age, was diagnosed with thrombocytopenia and. Refludan dosage: As Used: 4 Mg.

6235853-8 | Catheter Thrombosis, Fibrin D Dimer Increased
Adverse event was reported on Jun 05, 2009 by a Male patient taking Refludan (View Usage) (Dosage: 5.5 Mcg/kg/h Dose Gradually Increased To 46 Mcg/kg/h) was diagnosed with thrombocytopenia, catheterisation cardiac and. Location: GERMANY , child 6 years of age, Patient experienced the following unwanted or unexpected effects: catheter thrombosis, fibrin d dimer increased. During the same period patient was treated with PLATELETS (View Platelets Review and Platelets Label ), HEPARIN (8 Ie/kg/h, Dose Gradually Increased To 30 Ie/kg/h) (View Heparin Review and Heparin Label ), CALCIUM CITRATE (View Calcium Citrate Review and Calcium Citrate Label ).

6230794-4 | Chest Discomfort, Dyspnoea, Hypotension, Loss Of Consciousness
on May 21, 2009 Female patient from UNITED STATES , 88 years of age, was diagnosed with thrombocytopenia and was treated with Refludan (View Usage). Patient had the following side effects: chest discomfort, dyspnoea, hypotension, loss of consciousness. Refludan dosage: As Used: 4 Mg.

6197657-4 | Depressed Level Of Consciousness, Haemorrhage Intracranial, Melaena, Muscle Contractions Involuntary, Respiratory Arrest, Thrombocytopenia
on Apr 28, 2009 Male patient from FRANCE , 61 years of age, weighting 229.3 lb, was diagnosed with heparin-induced thrombocytopenia, hypertension, hypersensitivity, depression (What is depression?), pain (What is pain?) and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: depressed level of consciousness, haemorrhage intracranial, melaena, muscle contractions involuntary, respiratory arrest, thrombocytopenia. Refludan dosage: 100 Mg, Continuous. During the same period patient was treated with DOXAZOSIN MESYLATE (Unit Dose: 1 Mg) (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), NIFEDIPINE (Unit Dose: 30 Mg) (View Nifedipine Review and Nifedipine Label ), DIPHENHYDRAMINE HCL (Unit Dose: 25 Mg) (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), SERTRALINE HCL (Unit Dose: 150 Mg) (View Sertraline Hcl Review and Sertraline Hcl Label ), ACETAMINOPHEN AND HYDROCODONE BITARTRATE (Unk, As Req'd) (View Acetaminophen And Hydrocodone Bitartrate Review and Acetaminophen And Hydrocodone Bitartrate Label ).

6192383-X | Colon Cancer, Peripheral Ischaemia
Patient was taking Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: colon cancer, peripheral ischaemia on Apr 15, 2009 from SWITZERLAND Additional patient health information: Male patient , 64 years of age, was diagnosed with arterial thrombosis limb and. Refludan dosage: . During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROSTAGLANDIN E1 (View Prostaglandin E1 Review and Prostaglandin E1 Label ).

6190113-9 | Anaphylactic Shock, Cardiac Arrest
Adverse event was reported on Dec 10, 2008 by a Female patient taking Refludan (View Usage) (Dosage: Total Daily Dose: 36 Iu) was diagnosed with thrombectomy, anaesthesia and. Location: SWITZERLAND , 59 years of age, weighting 198.4 lb, Patient had the following side effects: anaphylactic shock, cardiac arrest (What is cardiac arrest?). During the same period patient was treated with ETOMIDATE (View Etomidate Review and Etomidate Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), SEVOFLURANE (View Sevoflurane Review and Sevoflurane Label ).

6188754-8 | Depressed Level Of Consciousness, Haemorrhage Intracranial, Melaena, Muscle Contractions Involuntary, Respiratory Arrest, Thrombocytopenia
on Apr 28, 2009 Male patient from FRANCE , 61 years of age, weighting 229.3 lb, was diagnosed with heparin-induced thrombocytopenia, hypertension, hypersensitivity, depression (What is depression?), pain (What is pain?) and was treated with Refludan (View Usage). After Refludan was administered, patient had the following side effects: depressed level of consciousness, haemorrhage intracranial, melaena, muscle contractions involuntary, respiratory arrest, thrombocytopenia. Refludan dosage: 100 Mg Continuous. During the same period patient was treated with DOXAZOSIN MESYLATE (Unit Dose: 1 Mg) (View Doxazosin Mesylate Review and Doxazosin Mesylate Label ), NIFEDIPINE (Unit Dose: 30 Mg) (View Nifedipine Review and Nifedipine Label ), DIPHENHYDRAMINE HCL (Unit Dose: 25 Mg) (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), SERTRALINE HCL (Unit Dose: 150 Mg) (View Sertraline Hcl Review and Sertraline Hcl Label ), ACETAMINOPHEN AND HYDROCODONE BITARTRATE (Unk, As Req'd) (View Acetaminophen And Hydrocodone Bitartrate Review and Acetaminophen And Hydrocodone Bitartrate Label ).

6181045-0 | Anaphylactic Shock, Cardiac Arrest
on Dec 10, 2008 Female patient from SWITZERLAND , 59 years of age, weighting 198.4 lb, was diagnosed with thrombectomy, anaesthesia and was treated with Refludan (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactic shock, cardiac arrest (What is cardiac arrest?). Refludan dosage: Total Daily Dose: 36 Iu. During the same period patient was treated with ETOMIDATE (View Etomidate Review and Etomidate Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), SEVOFLURANE (View Sevoflurane Review and Sevoflurane Label ).

6173245-0 | Colon Cancer, Peripheral Ischaemia
Patient was taking Refludan (View Usage). Patient had the following side effects: colon cancer, peripheral ischaemia on Apr 15, 2009 from SWITZERLAND Additional patient health information: Male patient , 64 years of age, was diagnosed with arterial thrombosis limb and. Refludan dosage: . During the same period patient was treated with HEPARIN (View Heparin Review and Heparin Label ), PROSTAGLANDIN E1 (View Prostaglandin E1 Review and Prostaglandin E1 Label ).